Barron's: Biotech Clones
2516 views
Rate Now: 1 2 3 4

average rating: 1.00 / 0 ratings
Created by Barrons
DESCRIPTION:

Date updated:02-17-2007

From Barron's 2-19-07:

"Generic competition for Biotech firms like Amgen and Genzyme drew a step closer Wednesday, when a bipartisan group in Congress introduced a bill to authorize Food and Drug Administration approval of generic biologic drugs. Traditional drugs have had 20 years of government-authorized generic competition, but there's been scarcely any competition for biologics -- those proteins or other fancy molecules typically made in cell cultures of genetically modified organisms. The lack of competition has enabled biotech companies to charge tens of thousands of dollars a year for treatments, creating lucrative businesses from even a small number of sick patients."

"So after Amgen's patents expire, the government and private insurers would love to see competitive pricing. In a Thursday conference call Sanford C. Bernstein biotech analyst Geoffrey Porges said: "Amgen is obviously the big target here."

symbol name last price % change open
  • +
  • TEVA
    Teva Pharmaceutic
  • $41.93
  • -2.08%
  • $42.86

From Barron's 2-19-07: "Backing the biogeneric bill from the get-go included the generic drug giant Teva Pharmaceutical (TEVA), which has been tooling up to make biogeneric drugs..."

People owning TEVA also tend to own: DELLTWXAAPLAPAAUYBPC

TheStreet.com Rating: B What is this?

  • +
  • ESRX
    Express Scripts
  • $57.33
  • +0.37%
  • $57.73

From Barron's 2-19-07: Other endorsers of the bill included "pharmacy benefit manager Express Scripts (ESRX), which released a study that said the country's annual savings from biogenerics could rise from $3.5 billion to $12 billion over the first ten years."

People owning ESRX also tend to own: AKAMBROCOGTCOHCPRTCTSHDNA

TheStreet.com Rating: B What is this?

  • +
  • NVO
    Novo Nordisk A S
  • $53.91
  • -1.12%
  • $52.84

From Barron's 2-19-07: "Human insulin made by genetically engineered critters is a low-hanging fruit, therefore, for the biogeneric ambitions of companies like Wockhardt, the Indian drug company. That's why vendors of recombinant human insulin like Novo Nordisk (NVO) have hightailed it into the sale of modified insulin products that improve upon the natural stuff."

People owning NVO also tend to own: AAPLACIAMZNBNICBICMGCNI

TheStreet.com Rating: B What is this?

  • +
  • SHPGY
    Shire Plc
  • $46.76
  • +2.70%
  • $46.77

From Barron's 2-19-07: "There already are potential challengers to the Genzyme and Amgen best sellers -- from Britain's Shire (SHPGY)... but those rivals have gone down the lengthy FDA approval process established for a biologics license application. The whole point of generic-drug regulation is to allow copycat versions of a proven drug to get to market more quickly."

People owning SHPGY also tend to own: ALCEGCMXDAVEKBMINDMIR

TheStreet.com Rating: C What is this?

  • +
  • BIIB
    Biogen Idec Inc
  • $46.47
  • -2.04%
  • $47.71

From Barron's 2-19-07: "Somewhat harder to knock off are the interferons, like those sold by Biogen (BIIB) and the anemia drugs Epogen and Aranesp sold by Amgen. But there's plenty of incentive for generic firms to try."

People owning BIIB also tend to own: APOLBRK-BDELLELOSLXKSAFMSGTL

TheStreet.com Rating: C+ What is this?

  • +
  • AMGN
    Amgen Inc.
  • $58.34
  • -2.20%
  • $60.00

From Barron's 2-19-07: The US govt, "under the Medicare program, spent over $3 billion on just three anemia drugs from Amgen (ticker: AMGN) in the fiscal year ended September 2005. So after Amgen's patents expire, the government and private insurers would love to see competitive pricing." "Somewhat harder to knock off are the interferons...but there's plenty of incentive for generic firms to try. Amgen's two red blood cell boosters kicked in nearly half of the company's $14.3 billion in 2006 sales..."

People owning AMGN also tend to own: APABACCCOPCVXDOWDRE

TheStreet.com Rating: B What is this?

  • +
  • NVS
    Novartis Ag Ads
  • $48.20
  • -1.59%
  • $48.88

From Barron's 2-19-07 "Once biogenerics became law, the FDA would need a long time to draw up regulations...But it would also make the biogeneric game less competitive for those who can afford to play it. Those who've shown an interest include manufacturers like Novartis (NVS), Pfizer (PFE), Teva and Barr Pharmaceuticals (BRL), as well as pharmacy benefit firms like Express Scripts and Medco Health Solutions (MHS)."

People owning NVS also tend to own: ANNAUYBACBHIERICFGE

TheStreet.com Rating: B- What is this?

  • +
  • PFE
    Pfizer Inc
  • $17.80
  • -1.98%
  • $18.32

From Barron's 2-19-07 "Once biogenerics became law, the FDA would need a long time to draw up regulations...But it would also make the biogeneric game less competitive for those who can afford to play it. Those who've shown an interest include manufacturers like Novartis (NVS), Pfizer (PFE), Teva and Barr Pharmaceuticals (BRL), as well as pharmacy benefit firms like Express Scripts and Medco Health Solutions (MHS)."

People owning PFE also tend to own: AAALLAPCBUDCOPCVXDOW

TheStreet.com Rating: C+ What is this?

previous next

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Cramer's Take on Top-Searched St...

Investors were spooked on Wednesday as bleak broad-based corporate outlooks and dismal employment data dominated headlines. Stocks experienced their largest drop in more t...

01.07.09 | 21:39 PM
Top Stocks With Insider Buying, ...

At Stockpickr.com, we strive to keep track of insider purchasing and buybacks each week. Here's the perfect setup in my mind: insiders buying the stock, the company buying ...

01.07.09 | 18:35 PM
'Fast Money' Portfolios of the Week

The traders of CNBC’s "Fast Money" think the current stock market is a traders' market. In order to play a traders' market, you have to nimble. You also have to know whic...

01.07.09 | 17:33 PM
What Should Pfizer Buy?

Pfizer (PFE) CEO Jeff Kindler has hinted that the world’s biggest drugmaker is open to a large-scale acquisition. “The real goal is to grow revenues," he told the Fina...

01.07.09 | 17:12 PM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZackAttack
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
Cartoon Thread
11.15.07 | 20:31 PM From author Gov. Peter Blagojevich
Full Disclosure
11.09.08 | 12:30 PM From author alchemist
more forums
Q. I am looking to invest monthly a...
01.07.09 | 23:17 PM Asked by richardjans

A. agree with mike, if you are new to
investing the market the best think you
can do right now is watch. The market
is not cheap in any way right now other
than the comparsion of where it just was
over a year ago. The market and economy
are going to a lot longer than what most
people think to become stable let alone
recover.

today 's lists
Low Priced NYSE Stocks

This portfolio consists of NYSE stocks that are trading for less than $5 per share and are profitable. more

TSC Ratings Downgrades

These stocks were downgraded by TheStreet.com Ratings on Dec. 29, 2008. more

Stocks Most Likely to Surprise

This list consists of stocks that are down 10% or more in the last year but may be poised to surprise us on the upside going forward. The basis for the list is as follows: ... more